Kancera Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 5


  • Stock Symbol
  • KAN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.16
  • (As of Thursday Closing)

Kancera General Information


Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Stock Exchange
Corporate Office
  • Nanna Svartz Väg 4
  • 171 65 Solna
  • Sweden
+46 08-501 000 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kancera Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.16 $0.16 $0.12 - $0.65 $19.7M 121M 418K -$0.07

Kancera Financials Summary

In Thousands,
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 8,006 31,741 10,064 24,553
Revenue 85 97 74 198
EBITDA (5,788) (5,849) (5,133) (5,281)
Net Income (5,691) (6,105) (5,173) (5,320)
Total Assets 11,521 6,568 11,574 14,741
Total Debt 0 0 0 63
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kancera Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kancera‘s full profile, request access.

Request a free trial

Kancera Comparisons

HQ Location
Total Raised
Post Valuation
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and
Solna, Sweden
5 As of 2024


dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
Amsterdam, Netherlands
00000000000 00.000


nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
West Perth, Australia
0 As of 0000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kancera Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Audion Therapeutics Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
Botanix Pharmaceuticals Corporation West Perth, Australia 0 00000 000000000 00000
Clinuvel Pharmaceuticals Corporation Melbourne, Australia 00 000000&0
You’re viewing 3 of 3 competitors. Get the full list »

Kancera Patents

Kancera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202401289-D0 New use Pending 31-Jan-2024
GB-202319559-D0 New use Pending 19-Dec-2023
GB-202006849-D0 New use Inactive 08-May-2020
US-11339183-B2 Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 Active 06-Jul-2018 0000000000 0
GB-201811169-D0 New compounds Inactive 06-Jul-2018 C07F9/6561
To view Kancera’s complete patent history, request access »

Kancera Executive Team (5)

Name Title Board Seat Contact Info
Peter Selin Chief Executive Officer
Thomas Olin Ph.D Founder, Executive Vice President , Chief Scientific Officer, Board Member
Martin Norin Ph.D Subject Matter Expert
Markus Jerling Ph.D Chief Medical Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Kancera Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kancera Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
iNovacia 17-Feb-2011 0000000000 00000 Drug Discovery 000000 00
To view Kancera’s complete acquisitions history, request access »

Kancera ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies











To view Kancera’s complete esg history, request access »

Kancera FAQs

  • When was Kancera founded?

    Kancera was founded in 2010.

  • Who is the founder of Kancera?

    Thomas Olin Ph.D is the founder of Kancera.

  • Who is the CEO of Kancera?

    Peter Selin is the CEO of Kancera.

  • Where is Kancera headquartered?

    Kancera is headquartered in Solna, Sweden.

  • What is the size of Kancera?

    Kancera has 5 total employees.

  • What industry is Kancera in?

    Kancera’s primary industry is Biotechnology.

  • Is Kancera a private or public company?

    Kancera is a Public company.

  • What is Kancera’s stock symbol?

    The ticker symbol for Kancera is KAN.

  • What is the current stock price of Kancera?

    As of 20-Jun-2024 the stock price of Kancera is $0.16.

  • What is the current market cap of Kancera?

    The current market capitalization of Kancera is $19.7M.

  • What is Kancera’s current revenue?

    The trailing twelve month revenue for Kancera is $84.8K.

  • Who are Kancera’s competitors?

    Audion Therapeutics, Botanix Pharmaceuticals, and Clinuvel Pharmaceuticals are competitors of Kancera.

  • What is Kancera’s annual earnings per share (EPS)?

    Kancera’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »